Kronos Bio Announces Participation in Medical and Investor Conferences in September
Kronos Bio (Nasdaq: KRON), a company developing small molecule therapeutics for cancers and diseases driven by deregulated transcription, has announced its participation in three upcoming conferences in September 2024:
1. H.C. Wainwright 26th Annual Global Investment Conference (Sept 9-11, New York): CEO Norbert Bischofberger will present on Sept 9.
2. AACR 15th Biennial Ovarian Cancer Research Symposium (Sept 20-21, Seattle): A poster on KB-0742, an oral CDK9 inhibitor, will be presented.
3. International Myeloma Society 21st Annual Meeting (Sept 25-28, Brazil): A Kronos Bio collaborator will give an oral presentation on p300 catalytic inhibition in multiple myeloma.
Live audio webcast and posters will be available on the Kronos Bio website.
Kronos Bio (Nasdaq: KRON), un'azienda che sviluppa terapeutiche a piccole molecole per tumori e malattie causate da trascrizione deregolata, ha annunciato la sua partecipazione a tre conferenze previste per settembre 2024:
1. H.C. Wainwright 26a Conferenza Globale di Investimento Annuale (9-11 settembre, New York): il CEO Norbert Bischofberger presenterà il 9 settembre.
2. AACR 15° Simposio Biennale sulla Ricerca sul Cancro Ovarico (20-21 settembre, Seattle): verrà presentato un poster su KB-0742, un inibitore orale di CDK9.
3. Società Internazionale del Mieloma 21a Riunione Annuale (25-28 settembre, Brasile): un collaboratore di Kronos Bio farà una presentazione orale sull'inibizione catalitica di p300 nel mieloma multiplo.
Il webcast audio in diretta e i poster saranno disponibili sul sito web di Kronos Bio.
Kronos Bio (Nasdaq: KRON), una empresa que desarrolla terapias de moléculas pequeñas para el cáncer y enfermedades impulsadas por la transcripción desregulada, ha anunciado su participación en tres conferencias que se llevarán a cabo en septiembre de 2024:
1. 26ª Conferencia Anual Global de Inversión H.C. Wainwright (9-11 de septiembre, Nueva York): el CEO Norbert Bischofberger presentará el 9 de septiembre.
2. 15º Simposio Bienal de Investigación sobre Cáncer de Ovario de AACR (20-21 de septiembre, Seattle): se presentará un póster sobre KB-0742, un inhibidor oral de CDK9.
3. 21ª Reunión Anual de la Sociedad Internacional del Mieloma (25-28 de septiembre, Brasil): un colaborador de Kronos Bio ofrecerá una presentación oral sobre la inhibición catalítica de p300 en el mieloma múltiple.
El webcast de audio en vivo y los pósters estarán disponibles en el sitio web de Kronos Bio.
Kronos Bio (Nasdaq: KRON)는 전이 조절로 인해 발생하는 암 및 질병을 위한 소분자 치료제를 개발하는 회사로, 2024년 9월에 열리는 세 가지 컨퍼런스에 참가할 것임을 발표했습니다:
1. H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스 (9월 9-11일, 뉴욕): CEO 노버트 비쇼프버거가 9월 9일에 발표합니다.
2. AACR 제15회 양성 난소암 연구 심포지엄 (9월 20-21일, 시애틀): 경구 CDK9 억제제인 KB-0742에 대한 포스터가 발표됩니다.
3. 국제 골수종 학회 제21회 연례 회의 (9월 25-28일, 브라질): Kronos Bio의 협력자가 다발성 골수종에서 p300 촉매 억제에 대한 구두 발표를 진행합니다.
실시간 오디오 웹캐스트 및 포스터는 Kronos Bio 웹사이트에서 확인할 수 있습니다.
Kronos Bio (Nasdaq: KRON), une entreprise développant des thérapies à molécules petites pour les cancers et les maladies causées par une transcription dérégulée, a annoncé sa participation à trois conférences à venir en septembre 2024 :
1. 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright (9-11 septembre, New York) : le PDG Norbert Bischofberger présentera le 9 septembre.
2. 15e Symposium Biennal de Recherche sur le Cancer de l'Ovaire de l'AACR (20-21 septembre, Seattle) : un poster sur KB-0742, un inhibiteur oral de CDK9, sera présenté.
3. 21e Réunion Annuelle de la Société Internationale du Myélome (25-28 septembre, Brésil) : un collaborateur de Kronos Bio fera une présentation orale sur l'inhibition catalytique de p300 dans le myélome multiple.
Un webinaire audio en direct et des affiches seront disponibles sur le site web de Kronos Bio.
Kronos Bio (Nasdaq: KRON), ein Unternehmen, das kleine Molekültherapeutika für Krebs und von deregulierter Transkription bedingte Krankheiten entwickelt, hat seine Teilnahme an drei bevorstehenden Konferenzen im September 2024 bekannt gegeben:
1. H.C. Wainwright 26. jährliche globale Investorenkonferenz (9.-11. September, New York): CEO Norbert Bischofberger wird am 9. September präsentieren.
2. AACR 15. biennale Symposium zur Forschung über Eierstockkrebs (20.-21. September, Seattle): Ein Poster über KB-0742, einen oralen CDK9-Inhibitor, wird präsentiert.
3. Internationale Myelom-Gesellschaft 21. Jahresversammlung (25.-28. September, Brasilien): Ein Mitarbeiter von Kronos Bio wird einen mündlichen Vortrag über die Katalysehemmung von p300 bei multiplem Myelom halten.
Ein Live-Audio-Webcast und Poster werden auf der Website von Kronos Bio verfügbar sein.
- Participation in multiple high-profile medical and investor conferences
- Presentation of clinical and preclinical data for KB-0742 in ovarian cancer
- Collaboration with Dana-Farber Cancer Institute on multiple myeloma research
- None.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the following upcoming conferences:
- H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9–11, 2024 in New York, NY
Kronos Bio President and Chief Executive Officer, Norbert Bischofberger, Ph.D., will present on Monday, September 9, at 2:30 p.m. ET - American Association for Cancer Research (AACR) 15th Biennial Ovarian Cancer Research Symposium, taking place September 20–21, 2024 in Seattle, WA
Kronos Bio Director of Translational Development, Luis Carvajal, Ph.D., will present a poster titled “Preclinical and clinical data support clinical expansion of KB-0742, an oral CDK9 inhibitor, into R/R ovarian cancer” on Saturday, September 21, 2024 (Author discussion from 11:30 a.m.–1:30 p.m. PT) - International Myeloma Society (IMS) 21st Annual Meeting, taking place September 25–28, 2024 in Rio de Janeiro, Brazil
Kronos Bio collaborator and Lead Scientist at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, Mariateresa Fulciniti, Ph.D., will give an oral presentation titled “p300 catalytic inhibition selectively disrupts IRF4 oncogenic programs impacting multiple myeloma cell growth and survival” on Saturday, September 28, 2024 (Abstract Session 10 from 10:00 a.m.–11:00 a.m. BRT)
A live audio webcast of the H.C. Wainwright presentation will be available under the Investors & Media section of the Kronos Bio website at www.kronosbio.com. A replay of the webcast will be available for 30 days following the event. The posters from the medical meetings will be available under the Science & Pipeline section of the Kronos Bio website.
About Kronos Bio
Kronos Bio, Inc. (Nasdaq: KRON) is a clinical-stage company dedicated to developing small molecule therapeutics that address deregulated transcription, a hallmark of cancer and other diseases. Our proprietary discovery engine decodes complex transcription factor regulatory networks to identify druggable cofactors. We screen for and optimize small molecules that target these cofactors in a tumor-specific context. These efforts have yielded a preclinical pipeline along with two internally developed drug candidates. Istisociclib (KB-0742) targets CDK9 to address MYC deregulation in solid tumors and KB-9558 targets p300 to address IRF4 dependence in multiple myeloma.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com or follow the Company on LinkedIn.
FAQ
What conferences will Kronos Bio (KRON) attend in September 2024?
What will Kronos Bio (KRON) present at the AACR Ovarian Cancer Research Symposium?
Who will represent Kronos Bio (KRON) at the H.C. Wainwright conference?
What research will be presented at the International Myeloma Society meeting related to Kronos Bio (KRON)?
